Drug Target Review – Issue #2 2017
Included in this issue: Technology convergence improves testing; Screening; Stem Cells; Targets; Mass Spectrometry; and Therapeutics in Alzheimer's disease...
List view / Grid view
Included in this issue: Technology convergence improves testing; Screening; Stem Cells; Targets; Mass Spectrometry; and Therapeutics in Alzheimer's disease...
An experimental treatment in mice allows the reprogramming of blood cells in order to promote the healing process of cutaneous wounds...
Investments are now being made to roll out this innovation across healthcare and broaden the scope of the research in this field.
A cancer drug for patients with certain types of leukaemia and lymphoma can also prevent reactions to some of the most common airborne allergens, according to a recent Northwestern Medicine study. The promising data from this pilot study could have greater implications for adults with food allergies.
The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) is establishing 15 new Research Training Groups to further support early research...
Licensing agreement will expand Oxford Genetics growing bio-therapeutic discovery, design and development service business.
Medically active substances are usually distributed via the blood – either directly or indirectly. In many diseases, however, it is vital to transport the active substance as efficiently as possible to the required target site. This is the case for diseases of the central nervous system, so the treatment of…
In a preclinical study in mice and human cells, researchers report that selectively removing old or 'senescent' cells from joints could stop and even reverse the progression of osteoarthritis.
The gene MAFK is known to be induced by the TGF-β signalling pathway, which is involved in breast cancer development. Scientists reported that the MAFK protein, in turn, induced cancerous behaviours in cells by switching on the breast cancer-associated gene GPNMB. MAFK thus represents a link between TGF-β signalling and…
BenevolentAI, a British artificial intelligence company, has partnered with MRC Technology (MRCT), a medical research charity, to explore drug discovery initiatives in the field of small molecules and antibodies.
Draper's Joe Charest explains how synthetic organoids can lead to safer drug testing, and why organ-on-a-chip technology is the future of drug discovery...
The human body’s peripheral nervous system could be capable of interpreting its environment and modulating pain, neuroscientists have established, after successfully studying how rodents reacted to stimulation.
Plasticell, a developer of stem cell technologies and cell-based therapies, has signed agreements with the Agency for Science, Technology and Research (A*STAR) and the Nanyang Technological University (NTU) to progress its therapeutic stem cell pipeline.
A new study has found that stem cell therapy can reduce lung inflammation in an animal model of chronic obstructive pulmonary disease (COPD) and cystic fibrosis. Although, still at a pre-clinical stage, these findings have important potential implications for the future treatment of patients.
Lone Friis and David Matthews discuss developability assessment of therapeutic antibodies, and Negin Mokhtari and colleagues explain nanoparticle-mediated enzyme delivery for application in cancer therapy...